Keywords: Neurocrine Biosciences, Boehringer Ingelheim, Licensing, GPR119, Type 2 diabetes

Neurocrine signs licensing deal worth up to $235 million with Boehringer for diabetes drug GPR119, hot on the heels of Abbott accord

Article | 18 June 2010

Print This

In the space of just 24 hours, USA-based Neurocrine Biosciences has signed a second major licensing deal, this time with independent ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in